Clinical Trial Update: A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating YTS109 Cells in relapsed/refractory autoimmune hemolytic anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• YTS109 cell (YTS109)

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Autoimmune Hemolytic Anemia | Phase 1 | Status: COMPLETED